Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice

IR Dunay, K Gajurel, R Dhakal… - Clinical microbiology …, 2018 - Am Soc Microbiol
Primary Toxoplasma gondii infection is usually subclinical, but cervical lymphadenopathy or
ocular disease can be present in some patients. Active infection is characterized by …

[HTML][HTML] Control of human toxoplasmosis

NC Smith, C Goulart, JA Hayward, A Kupz… - International journal for …, 2021 - Elsevier
Toxoplasmosis is caused by Toxoplasma gondii, an apicomplexan parasite that is able to
infect any nucleated cell in any warm-blooded animal. Toxoplasma gondii infects around 2 …

Drugs in development for toxoplasmosis: advances, challenges, and current status

PH Alday, JS Doggett - Drug design, development and therapy, 2017 - Taylor & Francis
Toxoplasma gondii causes fatal and debilitating brain and eye diseases. Medicines that are
currently used to treat toxoplasmosis commonly have toxic side effects and require …

HIV-associated opportunistic CNS infections: pathophysiology, diagnosis and treatment

LN Bowen, B Smith, D Reich, M Quezado… - Nature Reviews …, 2016 - nature.com
Nearly 30 years after the advent of antiretroviral therapy (ART), CNS opportunistic infections
remain a major cause of morbidity and mortality in HIV-positive individuals. Unknown HIV …

Treatment of toxoplasmosis: Current options and future perspectives

N Konstantinovic, H Guegan, T Stäjner, S Belaz… - Food and waterborne …, 2019 - Elsevier
Toxoplasmosis is a worldwide parasitic disease infecting about one third of humans, with
possible severe outcomes in neonates and immunocompromised patients. Despite …

[HTML][HTML] A systematic review of in vitro and in vivo activities of anti-Toxoplasma drugs and compounds (2006–2016)

M Montazeri, M Sharif, S Sarvi, S Mehrzadi… - Frontiers in …, 2017 - frontiersin.org
The currently available anti-Toxoplasma agents have serious limitations. This systematic
review was performed to evaluate drugs and new compounds used for the treatment of …

Small-molecule kinase inhibitors for the treatment of nononcologic diseases

Z Xie, X Yang, Y Duan, J Han… - Journal of medicinal …, 2021 - ACS Publications
Great successes have been achieved in developing small-molecule kinase inhibitors as
anticancer therapeutic agents. However, kinase deregulation plays essential roles not only …

Toxoplasmosis: Current and emerging parasite druggable targets

RE Hajj, L Tawk, S Itani, M Hamie, J Ezzeddine… - Microorganisms, 2021 - mdpi.com
Toxoplasmosis is a prevalent disease affecting a wide range of hosts including
approximately one-third of the human population. It is caused by the sporozoan parasite …

Promising Drug Targets and Compounds with Anti-Toxoplasma gondii Activity

M Silva, C Teixeira, P Gomes, M Borges - Microorganisms, 2021 - mdpi.com
Toxoplasmosis is a parasitic disease caused by the globally distributed protozoan parasite
Toxoplasma gondii, which infects around one-third of the world population. This disease …

The apicoplast is important for the viability and persistence of Toxoplasma gondii bradyzoites

SG Sanchez, E Bassot, A Cerutti… - Proceedings of the …, 2023 - National Acad Sciences
Toxoplasma gondii is responsible for toxoplasmosis, a disease that can be serious when
contracted during pregnancy, but can also be a threat for immunocompromised individuals …